<DOC>
	<DOCNO>NCT01270711</DOCNO>
	<brief_summary>The overall goal study assess monitor adherence effectiveness new prescribe guideline cabergoline . Specific objectives ass : 1 . The indication use cabergoline ( Parkinson , hyperprolactinemia , ) 2 . Prior treatment strategy patient start cabergoline treatment Parkinson 's Disease 3 . The percentage cabergoline user prescribe dos 3 mg per day 4 . Whether cabergoline user monitor echocardiography prior treatment . 5 . The incidence prevalence valvular fibrosis</brief_summary>
	<brief_title>Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities ( SUCRE )</brief_title>
	<detailed_description>involve random selection</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Hyperprolactinemia</mesh_term>
	<mesh_term>Cabergoline</mesh_term>
	<criteria>Treated cabergoline study period ( January 1st , 2006 end July 1st 2012 ) identify one 6 database : The Health Information Network , Health Search Database , Integrated Primary Care Information database , PHARMO , Aarhus hospital database , Universitaet Bremen Bremen Institute Prevention Patients eligibility date start July 1st 2007 ( mean would less one year valid data publication result EMEA review ) , exclude well patient whose eligibility end July 1st 2008 ( date SmPC change ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>compliance study</keyword>
	<keyword>effectiveness study</keyword>
	<keyword>hyperprolactinemia</keyword>
	<keyword>Parkinson 's disease</keyword>
	<keyword>retrospective cohort study</keyword>
</DOC>